JP2024543195A5 - - Google Patents

Info

Publication number
JP2024543195A5
JP2024543195A5 JP2024532270A JP2024532270A JP2024543195A5 JP 2024543195 A5 JP2024543195 A5 JP 2024543195A5 JP 2024532270 A JP2024532270 A JP 2024532270A JP 2024532270 A JP2024532270 A JP 2024532270A JP 2024543195 A5 JP2024543195 A5 JP 2024543195A5
Authority
JP
Japan
Prior art keywords
sequence
apoc3
rnai oligonucleotide
pharmaceutical composition
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024532270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543195A (ja
JP7877458B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080736 external-priority patent/WO2023102469A2/en
Publication of JP2024543195A publication Critical patent/JP2024543195A/ja
Publication of JP2024543195A5 publication Critical patent/JP2024543195A5/ja
Application granted granted Critical
Publication of JP7877458B2 publication Critical patent/JP7877458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024532270A 2021-12-01 2022-12-01 Apoc3発現を調節するための組成物及び方法 Active JP7877458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163264730P 2021-12-01 2021-12-01
US63/264,730 2021-12-01
PCT/US2022/080736 WO2023102469A2 (en) 2021-12-01 2022-12-01 Compositions and methods for modulating apoc3 expression

Publications (3)

Publication Number Publication Date
JP2024543195A JP2024543195A (ja) 2024-11-19
JP2024543195A5 true JP2024543195A5 (cg-RX-API-DMAC7.html) 2025-12-08
JP7877458B2 JP7877458B2 (ja) 2026-06-22

Family

ID=85018261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532270A Active JP7877458B2 (ja) 2021-12-01 2022-12-01 Apoc3発現を調節するための組成物及び方法

Country Status (12)

Country Link
US (2) US12234456B2 (cg-RX-API-DMAC7.html)
EP (1) EP4441218A2 (cg-RX-API-DMAC7.html)
JP (1) JP7877458B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240111757A (cg-RX-API-DMAC7.html)
CN (1) CN118355120A (cg-RX-API-DMAC7.html)
AR (1) AR127843A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022402155A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235941A1 (cg-RX-API-DMAC7.html)
IL (1) IL313220A (cg-RX-API-DMAC7.html)
MX (1) MX2024006740A (cg-RX-API-DMAC7.html)
TW (1) TW202330920A (cg-RX-API-DMAC7.html)
WO (1) WO2023102469A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026049536A1 (en) * 2024-08-30 2026-03-05 Olix Pharmaceuticals, Inc. RNAi AGENT TARGETING APOC3 GENE AND USE THEREOF
WO2026056961A1 (zh) * 2024-09-12 2026-03-19 瑞典瑞博科尔制药公司 寡核苷酸、寡核苷酸缀合物及组合物和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
EP1253199A1 (en) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
EP2405921A4 (en) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2723756B1 (en) * 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
EP3736334A1 (en) 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
WO2016081444A1 (en) * 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
MX2019002075A (es) 2016-08-23 2019-07-01 Dicerna Pharmaceuticals Inc Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos.
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
CN108239644B (zh) 2016-12-23 2021-05-28 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
US10675295B2 (en) * 2017-06-29 2020-06-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting HMGB1 expression
SG11201912178VA (en) 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
HRP20231063T1 (hr) * 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
CN111971051A (zh) * 2018-04-13 2020-11-20 迪克纳制药公司 用增加tm的核苷酸修饰的双链核酸抑制剂分子
US20220389430A1 (en) 2019-10-02 2022-12-08 Dicema Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
CN115397989A (zh) 2020-02-18 2022-11-25 阿尔尼拉姆医药品有限公司 载脂蛋白C3(APOC3)iRNA组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2023518409A5 (cg-RX-API-DMAC7.html)
JP2023536974A5 (cg-RX-API-DMAC7.html)
JP2024081668A5 (cg-RX-API-DMAC7.html)
JP7442574B2 (ja) Lpaの遺伝子発現の阻害のための組成物及び方法
JP2021518125A5 (cg-RX-API-DMAC7.html)
JP2024514880A5 (cg-RX-API-DMAC7.html)
JP2022501040A5 (cg-RX-API-DMAC7.html)
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
TWI881004B (zh) 用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
JP2023103244A5 (cg-RX-API-DMAC7.html)
JP2024516356A5 (cg-RX-API-DMAC7.html)
CN117701562A (zh) 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法
JP2023506181A5 (cg-RX-API-DMAC7.html)
JP2024515423A5 (cg-RX-API-DMAC7.html)
JP2020529197A5 (cg-RX-API-DMAC7.html)
JP2023529903A5 (cg-RX-API-DMAC7.html)
TW201446791A (zh) 用於調節mir-122之微小rna化合物及方法
JP2024538859A5 (cg-RX-API-DMAC7.html)
JP2023538284A5 (cg-RX-API-DMAC7.html)
JP2024516356A (ja) ケトヘキソキナーゼ(khk)を阻害するための組成物及び方法
JP2026062630A5 (cg-RX-API-DMAC7.html)
JP2023538283A (ja) 代謝症候群の治療のための組成物及び方法
JP2024522996A5 (cg-RX-API-DMAC7.html)
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的unaオリゴマー
JP2022534402A5 (cg-RX-API-DMAC7.html)